Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AlphaMed Pharmaceuticals has successfully expressed a humanized version of the therapeutic protein alpha 1-antitrypsin or AAT.
Subscribe to our email newsletter
AlphaMed scientists expressed their recombinant AAT utilizing the company’s proprietary production system in yeast. The yeast has been genetically altered to produce a molecule virtually identical to that which is manufactured by the human body.
AlphaMed is currently seeking developmental partners to continue its research for both topical and injectible or inhalable AAT therapies. The company has successfully completed its second round of financing and has initiated a third round to complete Phase I clinical trials and initiate Phase II clinical trials.